VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | The efficacy of asciminib in patients with CML who are resistant or intolerant to TKI therapy

Camille Kockerols, MD, Albert Schweitzer Hospital, Dordrecht, Netherlands, comments on the efficacy and tolerability of asciminib in patients with chronic myeloid leukemia (CML) who are intolerant or resistant to tyrosine kinase inhibitors (TKIs). Dr Kockerols explains that asciminib appears to be less efficacious in patients with CML who are resistant to ponatinib. With this knowledge, Dr Kockerols believes that asciminib dose modification or stem cell transplantation should be considered in these patients. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter